Rafael Holdings, INC 8-K filings

Rafael Holdings and Cyclo Therapeutics have agreed to merge, focusing on the development of Trappsol Cyclo for Niemann-Pick Disease Type C1.

Rafael Holdings, Inc. reports the resignation of director Mark McCamish and the appointment of Dr. Mark N. Stein to the board, effective August 5, 2024.

Rafael Holdings reported a significant net loss for the third quarter of fiscal 2024, primarily due to a large in-process research and development expense, while highlighting progress in its portfolio companies.

Rafael Holdings has finalized a complex restructuring of Cornerstone Pharmaceuticals, acquiring a controlling stake and consolidating related entities.

Rafael Holdings announced a profitable second quarter for fiscal year 2024, driven by unrealized gains on investments and increased its stake in Day Three Labs to a majority holding.

Rafael Holdings has significantly increased its ownership in Cornerstone Pharmaceuticals to approximately 67.03% through a debt and equity restructuring.

Rafael Holdings, Inc. held its annual meeting on January 10, 2024, where stockholders voted on the election of directors, ratification of the accounting firm, and executive compensation matters.